Infection‐related mortality after HLA‐identical and haploidentical hematopoietic cell transplantation using reduced‐intensity conditioning in an outpatient setting

Despite the improvements in supportive care for allogeneic‐hematopoietic cell transplantation (allo‐HCT) recipients, infectious complications and infection‐related mortality (IRM) continue to be a major issue for transplantation centers.

[1]  C. Solano,et al.  Hospital and outpatient models for Hematopoietic Stem Cell Transplantation: A systematic review of comparative studies for health outcomes, experience of care and costs , 2021, PloS one.

[2]  S. Pergam,et al.  Infection related mortality in adults and children undergoing allogeneic hematopoietic cell transplantation: An Australian registry report. , 2021, Transplantation and cellular therapy.

[3]  J. Sierra,et al.  Severe infections and infection-related mortality in a large series of haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamide , 2021, Bone Marrow Transplantation.

[4]  D. Gómez-Almaguer,et al.  Outpatient Haploidentical Stem Cell Transplantation Using Post-Transplant Cyclophosphamide Is Safe and Feasible. , 2021, Transplantation and cellular therapy.

[5]  E. Albert,et al.  Patterns of infection and infectious-related mortality in patients receiving post-transplant high dose cyclophosphamide as graft-versus-host-disease prophylaxis: impact of HLA donor matching , 2020, Bone Marrow Transplantation.

[6]  A. van Belkum,et al.  Innovative and rapid antimicrobial susceptibility testing systems , 2020, Nature Reviews Microbiology.

[7]  L. Galli,et al.  Infections after allogenic transplant with post-transplant cyclophosphamide: impact of donor HLA-matching. , 2020, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[8]  A. Vekhoff,et al.  Infectious complications after post‐transplantation cyclophosphamide and anti‐thymocyte globulin‐based haploidentical stem cell transplantation , 2019, British journal of haematology.

[9]  S. Montoto,et al.  Death after hematopoietic stem cell transplantation: changes over calendar year time, infections and associated factors , 2019, Bone Marrow Transplantation.

[10]  C. Teng,et al.  Haploidentical allogeneic hematopoietic stem cell transplantation increases the risk of cytomegalovirus infection in adult patients with acute leukemia , 2019, Transplant infectious disease : an official journal of the Transplantation Society.

[11]  M. Akhtari,et al.  Increased risk of 100-day and 1-year infection-related mortality and complications in haploidentical stem cell transplantation , 2019, Journal of blood medicine.

[12]  A. Nademanee,et al.  Incidence and Risk Factors of CMV Reactivation after Haploidentical Hematopoietic Cell Transplantation Using High-Dose Post-Transplant Cyclophosphamide - Possible Role of Donor KIR Genotypes , 2018, Blood.

[13]  Chutima Kunacheewa,et al.  Risk of febrile neutropenia among patients with multiple myeloma or lymphoma who undergo inpatient versus outpatient autologous stem cell transplantation: a systematic review and meta-analysis , 2018, BMC Cancer.

[14]  D. Gómez-Almaguer,et al.  Assessing the efficacy of an ambulatory peripheral blood hematopoietic stem cell transplant program using reduced intensity conditioning in a low-middle-income country , 2018, Bone Marrow Transplantation.

[15]  P. Rancoita,et al.  A New Clinicobiological Scoring System for the Prediction of Infection-Related Mortality and Survival after Allogeneic Hematopoietic Stem Cell Transplantation. , 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[16]  T. Walsh,et al.  Multidrug‐resistant Enterobacteriaceae, Pseudomonas aeruginosa, and vancomycin‐resistant Enterococcus: Three major threats to hematopoietic stem cell transplant recipients , 2017, Transplant infectious disease : an official journal of the Transplantation Society.

[17]  P. Westervelt,et al.  Epidemiology of infections following haploidentical peripheral blood hematopoietic cell transplantation , 2016, Transplant infectious disease : an official journal of the Transplantation Society.

[18]  C. Carlo-Stella,et al.  Infections after T‐replete haploidentical transplantation and high‐dose cyclophosphamide as graft‐versus‐host disease prophylaxis , 2015, Transplant infectious disease : an official journal of the Transplantation Society.

[19]  Karl Frauendorfer,et al.  One million haemopoietic stem-cell transplants: a retrospective observational study. , 2015, The Lancet. Haematology.

[20]  C. Huff,et al.  Absence of post-transplantation lymphoproliferative disorder after allogeneic blood or marrow transplantation using post-transplantation cyclophosphamide as graft-versus-host disease prophylaxis. , 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[21]  K. Ballen,et al.  Risk factors for invasive fungal disease after allogeneic hematopoietic stem cell transplantation: a single center experience. , 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[22]  S. Lee,et al.  Infectious complications following allogeneic stem cell transplantation: reduced‐intensity vs. myeloablative conditioning regimens , 2013, Transplant infectious disease : an official journal of the Transplantation Society.

[23]  Lanping Xu,et al.  The incidence and risk factors of invasive fungal infection after haploidentical haematopoietic stem cell transplantation without in vitro T-cell depletion. , 2012, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[24]  Michael Boeckh,et al.  Reduced mortality after allogeneic hematopoietic-cell transplantation. , 2010, The New England journal of medicine.

[25]  G. Sauvageau,et al.  High incidence of invasive aspergillosis associated with intestinal graft-versus-host disease following nonmyeloablative transplantation. , 2007, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[26]  F. Dulley,et al.  Evaluation of early hospital discharge after allogeneic bone marrow transplantation for chronic myeloid leukemia. , 2007, Sao Paulo medical journal = Revista paulista de medicina.

[27]  S. Lee,et al.  Infectious complications and outcomes after allogeneic hematopoietic stem cell transplantation in Korea , 2004, Bone Marrow Transplantation.

[28]  M. Maris,et al.  Incidence and outcome of bacterial and fungal infections following nonmyeloablative compared with myeloablative allogeneic hematopoietic stem cell transplantation: a matched control study. , 2002, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[29]  P. Moreau,et al.  Longitudinal study of bacterial, viral, and fungal infections in adult recipients of bone marrow transplants. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[30]  W. Leisenring,et al.  Epidemiology of Aspergillus infections in a large cohort of patients undergoing bone marrow transplantation. , 1997, The Journal of infectious diseases.

[31]  M. Solh,et al.  Comparison of Outcomes of Hematopoietic Cell Transplants from T-Replete Haploidentical Donors Using Post-Transplantation Cyclophosphamide with 10 of 10 HLA-A, -B, -C, -DRB1, and -DQB1 Allele-Matched Unrelated Donors and HLA-Identical Sibling Donors: A Multivariable Analysis Including Disease Risk In , 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.